Literature DB >> 32820802

Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments.

Frédéric Clarembeau1,2, Georgia Bale1, Nicolas Lanthier1,2.   

Abstract

End-stage chronic liver diseases are often associated with insulin resistance (IR) and diabetes mellitus (DM). Indeed, to quantify insulin sensitivity the euglycemic clamp technique was utilized, allowing the following to be stated: in small groups of patients, an IR in almost all cirrhotic patients can be observed, compared with a control group. Additionally, it has been demonstrated that IR in cirrhosis is linked to a decreased peripheral (muscle) glucose uptake rather than an increased liver glucose production. The homoeostasis model of IR (HOMA-IR) technique, devised only later, was then exploited to assess this same phenomenon in a larger sample population. The research established that even in patients with preserved liver function, cirrhosis is associated with significant alterations in glucose homoeostasis levels. The purpose of the present paper is to present the current research around the affiliation of cirrhosis and IR, discuss potential mechanisms explaining the association between cirrhosis and IR (i.e. endocrine perturbation, liver inflammation, altered muscle mass and composition, altered gut microbiota and permeability), complications that can arise as well as treatment options, through a critical review of the literature surrounding this subject. This research will also be investigating the beneficial impact, if there is any, of identifying and curing IR in patients with cirrhosis.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  cirrhosis; diabetes; insulin resistance; metabolic syndrome; microbiota; sarcopenia

Mesh:

Substances:

Year:  2020        PMID: 32820802     DOI: 10.1042/CS20200022

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  3 in total

1.  Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B-A Retrospective Cohort Study.

Authors:  Qing-Xia Wang; Jiao Xue; Mei-Jie Shi; Yu-Bao Xie; Huan-Ming Xiao; Sheng Li; Ming Lin; Xiao-Ling Chi
Journal:  Diabetes Metab Syndr Obes       Date:  2022-08-02       Impact factor: 3.249

Review 2.  Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?

Authors:  Nicolas Lanthier; Nathalie Delzenne
Journal:  Cells       Date:  2022-08-31       Impact factor: 7.666

3.  Glycoursodeoxycholic acid ameliorates diet-induced metabolic disorders with inhibiting endoplasmic reticulum stress.

Authors:  Lele Cheng; Tao Chen; Manyun Guo; Peining Liu; Xiangrui Qiao; Yuanyuan Wei; Jianqing She; Bolin Li; Wen Xi; Juan Zhou; Zuyi Yuan; Yue Wu; Junhui Liu
Journal:  Clin Sci (Lond)       Date:  2021-07-30       Impact factor: 6.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.